Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present)

Misha Kabir1,2 | Rishi Fofaria1 | Naila Arebi1,2 | Paul Bassett3 | Phil J Tozer1,2 | Ailsa L Hart1,2 | Siwan Thomas-Gibson1,2 | Adam Humphries1,2 | Noriko Suzuki1,2 | Brian Saunders1,2 | Janindra Warusavitarne1,2 | Omar Faiz1,2 | Ana Wilson1,2

1St Mark’s Hospital, Harrow, UK  
2Imperial College London, London, UK  
3Stats Consultancy, Amersham, UK

Correspondence  
Dr. Misha Kabir, Clinical Research Fellow, Wolfson Unit for Endoscopy, St Mark’s Hospital, Watford Road, Harrow HA1 3UJ, UK.  
Email: misha.kabir1@nhs.net

Summary

Background: The prognosis of dysplasia in patients with IBD is largely determined from observational studies from the pre-videoendoscopic era (pre-1990s) that does not reflect recent advances in endoscopic imaging and resection.

Aims: To better understand the risk of synchronous colorectal cancer and metachronous advanced neoplasia (ie high-grade dysplasia or cancer) associated with dysplasia diagnosed in the videoendoscopic era, and to stratify risk according to a lesion’s morphology, endoscopic resection status or whether it was incidentally detected on biopsy of macroscopically normal colonic mucosa (ie invisible).

Methods: A systematic search of original articles published between 1990 and February 2020 was performed. Eligible studies reported on incidence of advanced neoplasia at follow-up colectomy or colonoscopy for IBD-dysplasia patients. Quantitative and qualitative analyses were performed.

Results: Thirty-three studies were eligible for qualitative analysis (five for the meta-analysis). Pooled estimated proportions of incidental synchronous cancers found at colectomy performed for a pre-operative diagnosis of visible high-grade dysplasia, invisible high-grade dysplasia, visible low-grade dysplasia and invisible low-grade dysplasia were 13.7% (95% CI 0.0-54.1), 11.4% (95% CI 4.6-20.3), 2.7% (95% CI 0.0-7.1) and 2.4% (95% CI 0.0-8.5) respectively. The lowest incidences of metachronous advanced neoplasia, for dysplasia not managed with immediate colectomy but followed up with surveillance, tended to be reported by the studies where high definition imaging and/or chromoendoscopy was used and endoscopic resection of visible dysplasia was histologically confirmed.

Conclusions: The prognosis of IBD-dysplasia diagnosed in the videoendoscopic era appears to have been improved but the quality of evidence remains low. Larger, prospective studies are needed to guide management.

PROSPERO registration no: CRD42019105736.
Patients with ulcerative colitis or Crohn’s disease colitis have an increased risk of colorectal cancer. The overall cancer prevalence was reported as 3.7% in the landmark meta-analysis by Eaden et al published in 2001. The cumulative probabilities of developing cancer were reported to be 2% by 10 years, 8% by 20 years and 18% by 30 years of disease duration. However, more recent population-based cohort studies and updated meta-analyses suggest that the risk of cancer is lower than previously thought, although overall this rate is still significantly higher than the non-IBD population. Cumulative risks of colorectal cancer in a more recent meta-analysis were 1% by 10 years, 2% by 20 years and 5% after more than 20 years of disease duration. It is unclear whether this reduced incidence of IBD cancer is related to optimisation in endoscopic surveillance, medical therapy or timely colectomy in the last decade. A Cochrane systematic review and meta-analysis observed lower incidence rates of cancer in IBD patients on surveillance compared to IBD patients not on surveillance. The ratio of early stage vs late stage cancers detected was also higher in the surveillance group compared to the nonsurveillance group. Taking tumour stage into account, ulcerative colitis patients are still more likely to die of colorectal cancer than patients without ulcerative colitis, but this risk appears to be declining over time.

The purpose of colonoscopic surveillance is to detect dysplasia which is defined as an unequivocal neoplasia of the epithelium confined to the basement membrane, without invasion into the lamina propria. The 21st century has witnessed advances in endoscopic surveillance technology such as high definition imaging and chromoendoscopy, which have led to increased detection of dysplasia. Dysplasia incidence rates were reported to have almost doubled from the 1993-2002 to the 2003-2012 time period in the St Mark’s surveillance cohort. Advanced dysplasia resection techniques such as endoscopic submucosal dissection and hybrid techniques have also allowed the resection of flat nonpolypoid lesions, previously destined for surgical management only. However, the impact of these advances on rates of metachronous advanced neoplasia developing during surveillance follow-up remains uncertain. As there are no randomised controlled trials comparing endoscopic surveillance with colectomy, international society guidelines have based their recommendations for the management of higher risk lesions on small numbers of observational studies. The small patient cohorts, limited follow-up times, contradictory lesion characterisation terminology and inclusion of data from the pre-videoendoscopic era, have limited the interpretation of outcomes from these studies. The most recent international guidelines are summarised in Table S1.

If dysplasia is able to be completely endoscopically resected, all guidelines recommend continued regular colonoscopic surveillance. If dysplasia is endoscopically unresectable or invisible (ie the dysplasia is detected on random biopsy of the colonic mucosa without any corresponding visible dysplastic lesion detectable by the endoscopist), guidance on management is less clear due to the wide variation in reported progression rates to advanced neoplasia.
progression rate) during surveillance follow-up of 6 months or more after:
a. Endoscopic resection of visible LGD and HGD (polypoid vs nonpolypoid)
b. Detection of invisible LGD and HGD
c. Detection of indefinite for dysplasia

2 | METHODS

2.1 | Search strategy and study selection

The present systematic review is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An a priori protocol was followed and registered at the international prospective register of systematic reviews (PROSPERO registration no. CRD42019105736). An electronic literature search of English language articles was performed using MEDLINE, EMBASE and the Cochrane Library Database, from the dates 1990 to February 2020. The full electronic search strategy can be viewed in Appendix 1 and was designed and conducted with the assistance of an experienced medical librarian. Study eligibility for inclusion was undertaken independently by two researchers (MK and RF) and discrepancies resolved after consensus discussion. Meta-analyses, randomised controlled and observational studies were included if the intervention and outcome met the eligibility criteria. Reference lists of the included full-text articles were also scanned for additional articles. Conference proceedings were also considered.

The inclusion criteria were as follows: (a) studies of ulcerative colitis, Crohn’s colitis and indeterminate colitis patients who had a colectomy or at least one follow-up colonoscopy performed after an initial diagnosis of dysplasia was made on colonoscopy; (b) the cohort could be subdivided according to the dysplasia severity grading (ie indefinite, low-grade and high-grade), endoscopic visibility and lesion morphology (polypoid or nonpolypoid as per the SCENIC criteria); and (c) reported on the incidence of advanced neoplasia found during surveillance or in the colectomy specimen according to the endoscopic visibility, morphology and grade of the index dysplasia. Articles were excluded if all or most patients included had their dysplasia diagnosed in the pre-videoendoscopic era, which was taken to be before 1990, or it was not possible to extract incidence rates according to visibility, morphology and severity of the index dysplasia from the data provided. Studies reporting on primary sclerosing cholangitis patients were included, except for those cohorts with exclusively these patients as this could skew the data. In the event where a number of publications had been reported by the same group, with duplication of results from the same dataset, the most recent publication was included for analysis of each outcome. Dysplasia detected on random biopsy of the colonic mucosa without any corresponding visible dysplastic lesion detectable by the endoscopist was termed ‘invisible’.

2.2 | Data extraction

Data were extracted independently by two investigators (MK and RF). All discrepancies were resolved and consensus achieved after discussion. For each study included, data were retrieved on the country where it was performed, year of publication, enrolment period, study design, subclassification of the IBD, colitis extent, number of patients with dysplasia within the extent of colitis, proportion of endoscopically resected dysplasia, whether the dysplasia histology had been reviewed by a second gastrointestinal expert histopathologist, proportion with multifocal dysplasia or primary sclerosing cholangitis, the mean or median follow-up time, and the number and incidence rate of new histologically proven high-grade dysplasia and colorectal cancer cases found on follow-up or at colectomy.

2.3 | Primary outcomes

2.3.1 | Prevalent cancer rate

Incidental cancers found anywhere in the colectomy specimen when colectomy surgery was performed for a pre-operative diagnosis of dysplasia (usually performed within 6 months of the dysplasia diagnosis).

2.3.2 | Advanced neoplasia progression rate

Incidence of new HGD or colorectal cancer found during surveillance follow-up performed more than 6 months after a LGD diagnosis, or incidence of new cancer found during surveillance follow-up performed more than 6 months after a HGD diagnosis.

2.4 | Quality and risk of bias assessment

Three of the investigators (MK, RF and NA) assessed the methodological quality and risk of bias of every study using a modified Joanna Briggs Institute Critical Appraisal Checklist for studies reporting on prevalence (Table A2). The overall quality of the evidence for each outcome was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria and are detailed in the summary of findings Tables 1 and 2.

2.5 | Statistical methods

Meta-analysis methods were used to pool together the cancer prevalence rates from different studies. The Stata software package (version 15.1) was used. The DerSimonian-Laird random effects method was used for the analysis, regardless of the degree of heterogeneity between the study results. The Freeman-Tukey double arcsine transformation was performed before analysis, which was used to stabilise...
the variances when the proportions were close to 0 and 1, and therefore the normal approximation to the binomial distribution did not hold. The heterogeneity between studies was assessed based on the significance of the between-study heterogeneity, and also on the size of the $I^2$ value. Substantial heterogeneity was assumed if the $I^2$ value was above 50% or the chi-squared test $P$ value was less than 0.05.

### RESULTS

#### Systematic search results

The search strategy is described in detail in the PRISMA flow diagram (Figure 1). The initial search yielded 5095 citations and from these 33 studies were eligible for inclusion. All of these were observational studies: one was a prospective cohort study; 18 were retrospective cohort studies; and 14 were retrospective case series (see Table A2). All studies were from academic centres which were based in the USA ($n = 21$), UK ($n = 4$), Japan ($n = 4$), the Netherlands ($n = 2$), Korea ($n = 1$), Italy ($n = 1$), Belgium ($n = 1$) and Portugal ($n = 1$). Twenty of the eligible studies included only ulcerative colitis patients, one study included only Crohn’s colitis patients and 12 studies included patients with ulcerative colitis and Crohn’s colitis and/or indeterminate colitis.

Twenty-three (69.7%) of the studies satisfied at least 80% of the 10 criteria in the modified Joanna Briggs Institute Critical Appraisal Checklist for studies reporting on prevalence (detailed in Table A2). Most of the studies adequately described the study

---

**TABLE 1** GRADE summary of findings table—pooled estimates of prevalent cancer rate\(^a\) according to dysplasia grading and endoscopic visibility

| Patient group            | Number of studies | Study design   | Total study population | Number of prevalent cancers | Prevalent cancer rate\(^a\) pooled estimate % (95% confidence interval) | Between study heterogeneity | GRADE quality of evidence\(^d\) |
|--------------------------|-------------------|----------------|------------------------|----------------------------|------------------------------------------------------------------------|-----------------------------|-------------------------------|
| Visible HGD              | Three             | Observational | 126                    | 35                         | 13.7% (0.0%-54.1%)                                                   | <0.001                      | 91.9%                         |
| Invisible HGD            | Two               | Observational | 69                     | 9                          | 11.4% (4.6%-20.3%)                                                   |                               |                               |
| Visible LGD              | Three             | Observational | 145                    | 5                          | 2.7% (0.2%-7.1%)                                                    | 0.29                        | 18.9%                         |
| Invisible LGD            | Three             | Observational | 208                    | 6                          | 2.4% (0.0%-8.5%)                                                    | 0.12                        | 53.3%                         |
| Indefinite for dysplasia | Two               | Observational | 60                     | 1                          | 1.2% (0.0%-6.6%)                                                    |                               |                               |

**Abbreviations:** HGD, high-grade dysplasia; LGD, low-grade dysplasia.

\(^a\)Prevalent cancer rate is the proportion of patients who have colectomy surgery performed for a pre-operative diagnosis of dysplasia (usually performed within 6 mo of the dysplasia diagnosis) and a colorectal cancer is found incidentally anywhere in the colectomy specimen.

\(^b\)Insufficient studies to evaluate heterogeneity between studies.

\(^c\)I\(^2\) value above 50% assumes substantial between study heterogeneity.

\(^d\)Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Working group grades of evidence: With prognostic outcomes, longitudinal cohort studies are initially rated as high quality and downgraded by one level or more if one or more of the following apply: 1. High risk of bias in study design as indicated by modified Joanna Briggs Institute Critical Appraisal Checklist median scores of less than eight out of 10 or failure of most of the studies to adequately measure the proportion of dysplasia which was endoscopically resected pre-operatively, which is an important confounding factor. 2. Inconsistency of results between the studies. Where calculated this is reflected by high between-study heterogeneity ($I^2 >50\%$), 3. Imprecision of results if there is a wide 95% confidence interval around the pooled estimate. 4. Indirectness of evidence where the studied population does not correspond to patients who have a colectomy for a pre-operative diagnosis of dysplasia now. This is likely to be in the case of patients with invisible dysplasia as most of the data from these studies are taken from a time period before high-definition imaging and chromoendoscopy were adopted into clinical practice. 5. High risk of publication bias is suspected for all outcomes due to the very small number of studies published and the suspected exclusion of the smallest population studies.

\(^*\)Chi-squared heterogeneity test: $P$ value $< 0.05$ considered statistically significant.
| Dysplasia grade, morphology and resection status | No. and design of studies included | Total no. patients included | Advanced neoplasia progression rates<sup>a</sup> | Colorectal cancer progression rates<sup>b</sup> | GRADE quality of evidence<sup>d</sup> |
|------------------------------------------------|-----------------------------------|-----------------------------|-----------------------------------------------|----------------------------------------|---------------------------------------|
| Visible polypoid HGD post-polypectomy          | Seven observational studies       | At least 26 (from five studies<sup>3</sup>) | 0.0%-40.0% at median 4 y | 0.0%-40.0% at median 4 y | @OOO VERY LOW Due to risk of bias, inconsistency, publication bias |
| Visible non-polypoid HGD post-polypectomy      | Six observational studies         | At least 11 (from four studies<sup>3</sup>) | 0.0% at median 2 y 50.0% at median 11 y | 0.0% at median 2 y 50.0% at median 11 y | @OOO VERY LOW Due to risk of bias, inconsistency, indirectness, publication bias |
| Invisible HGD                                 | None                              | N/A                          | N/A                                           | N/A                                    | --                                    |
| Visible polypoid LGD post-polypectomy          | Nine observational studies        | At least 143 (from six studies<sup>4</sup>) | 0.0%-5.0% at median 1 y 0.0%-23.0% at median 5 y | 0.0%-4.5% at median 2 y 0.0%-13.6% at median 4 y | @OOO LOW Due to inconsistency, publication bias |
| Visible non-polypoid LGD post-polypectomy      | Eight observational studies       | At least 29 (from six studies<sup>3</sup>) | 0.0%-22.2% at median 2 y 40.0% at median 10 y | 0.0%-22.2% at median 2 y 40.0% at median 10 y | @OOO VERY LOW Due to risk of bias, inconsistency, indirectness, publication bias |
| Invisible LGD                                 | Eight observational studies       | 186                          | 4.6%-44.0% at median 2 y                      | 0.0%-28.0% at median 2 y               | @OOO LOW Due to inconsistency, indirectness |
| Indefinite for dysplasia                      | Six observational studies         | 252                          | 2.4%-14.6% at median 2 y 4.8%-36.5% at median 5 y | 0.0%-1.2% at median 2 y 5.1%-14.3% at median 4 y | @OOO VERY LOW Due to risk of bias, inconsistency, publication bias |

**Abbreviations:** HGD, high-grade dysplasia; LGD, low-grade dysplasia.

<sup>a</sup>The 'advanced neoplasia progression rate' is the incidence of new high-grade dysplasia or colorectal cancer found during surveillance follow-up performed more than 6 mo after a low-grade dysplasia diagnosis, or incidence of new cancer found during surveillance follow-up performed more than 6 mo after a high-grade dysplasia diagnosis.

<sup>b</sup>The 'colorectal cancer progression rate' is the incidence of new colorectal cancer found during surveillance follow-up performed more than 6 mo after the dysplasia diagnosis.

<sup>c</sup>The other studies did not specify number of patients by dysplasia grading but number of polyps by dysplasia grading so number of patients included could not be extracted from these studies.

<sup>d</sup>Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Working group grades of evidence: With prognostic outcomes, longitudinal cohort studies are initially rated as high quality and downgraded by one level or more if one or more of the following apply: 1. High risk of bias in study design as indicated by modified Joanna Briggs Institute Critical Appraisal Checklist median scores of less than eight out of 10; or very small sample size or median follow-up time is less than 36 mo; or failure of most of the studies to adequately measure the proportion of dysplasia located within the colitis extent and which was endoscopically resected, which are important confounding factors. 2. Inconsistency of results between the studies with wide variations in incidence rates between studies. 3. Indirectness of evidence where the studied population does not correspond to patients who are being follow-up after a diagnosis of dysplasia: patients with invisible dysplasia as most of the data from these studies are taken from a time period before high-definition imaging and chromoendoscopy were adopted into clinical practice; where included patients in the study had to meet a specific criteria, for example size greater than 10 mm. 4. High risk of publication bias is suspected where there are a small number of studies published or a large proportion of case series selected for a specific intervention like endoscopic submucosal dissection.

Subjects in detail (93.9%; n = 31), there was sufficient follow-up of the included study participants (93.9%), appropriate statistical analyses were used (100%), and objective, standard criteria for the confirmation of IBD, dysplasia and their subgroup diagnoses were utilised (97.0%; n = 32). Only 21.2% (n = 7) of the studies had an adequate sample size of 75 patients or more. Forty-two percent (n = 14) of the study populations was not felt to be representative of the target population in view of the selective inclusion/exclusion criteria used, for example in case series where only large LGD lesions for endoscopic submucosal dissection were recruited. Just over half (51.5%; n = 17) of the studies did not include important confounding factors such as specifying whether the dysplasia was located inside or outside of the extent of colitis or was successfully endoscopically resected before colectomy or follow-up. Fifteen
percent (n = 5) of the studies did not report whether the dysplasia diagnosis was confirmed by a second expert histopathologist. According to the GRADE criteria, overall the evidence supporting the outcomes produced from these studies was deemed to be of low quality (our confidence in the estimate is limited) or very low quality (we have very little confidence in the estimate and the true prognosis is likely to be substantially different from the estimate). Further explanation of the grading of evidence is provided in the summary of findings Tables 1 and 2.

Five studies met the inclusion criteria to extract the primary outcome: prevalent cancer rates found at colectomy for a pre-operative diagnosis of dysplasia. Pooled estimates of this outcome from these five studies were calculated using meta-analysis methods. The results are detailed further in Section 3.2. Twenty-five studies met the inclusion criteria to extract the primary outcome: Advanced neoplasia progression rates during surveillance follow-up after the index diagnosis of dysplasia. Due to heterogeneity in the composition of the various study cohorts included, pooled meta-analysis was not deemed appropriate for this outcome. For example, in the post-polypectomy cohorts, the inclusion of mixtures of high-grade and low-grade dysplastic polyps made extraction of accurate incidence data difficult. A median or mean follow-up time was reported by each included study. However, follow-up times for each individual patient from each study could not be extracted. It was felt that calculating pooled estimates of advanced neoplasia incidence rates based on the pooled median/mean follow-up times reported by each study, rather than individual patient follow-up times, would be inaccurate and potentially misleading. Therefore, qualitative syntheses only have been conducted for the advanced neoplasia progression rates.

### 3.2 | Prevalent cancer rate

Three of the included cohort studies and two of the case series reported on prevalent cancer rate and are described in more detail in Table A3. Pooled estimates of the prevalent cancer rates were calculated using meta-analysis methods, and the results are summarised in Table 1.

#### 3.2.1 | Visible HGD

Two cohort studies and one case series reported on the rates of prevalent cancer found in the surgical colectomy specimen resected
soon after a pre-operative diagnosis of visible HGD where 94% to 100% had not been endoscopically resected pre-operatively. The prevalent cancer rate varied from 0% (n = 0/26), 20% (n = 1/5) to 35.8% (n = 34/95). The studies with the highest prevalent cancer rates only included cases where the dysplasia was specified to be within inflamed mucosa, rather than proximal to it. The pooled estimated cancer prevalence rate from all these studies was 13.7% (95% CI: 0.0%-54.1%). The results are shown in a forest plot in Figure A4. The significant heterogeneity test (P = 0.29) was calculated statistic = 19%; I2 statistic value of 91.9% suggest considerable heterogeneity between studies.

3.2.2 | Invisible HGD

Two cohort studies reported prevalent cancer rates after a pre-operative diagnosis of invisible HGD as 22.2% (n = 8/36) where the dysplasia was specified to be within inflamed mucosa and 3.0% where it was not specified (n = 1/33). The pooled estimated cancer prevalence rate from all these studies was 11.4% (95% CI: 4.6%-20.3%). The number of studies was too small to be able to assess heterogeneity for this patient group.

3.2.3 | Visible LGD

Two cohort studies and one case series reported prevalent cancer rates with a pre-operative diagnosis of visible LGD of 0.0% (n = 0/24), 2.5% (n = 2/79) and 7.1% (n = 3/42). Here, both the studies with the lowest and highest prevalence rates included cases where only dysplasia found within a colitis-affected segment were included. Krugliak Cleveland et al found a prevalence rate of 0.0%, and included the most recent cohort of patients (2005-2014) who all had surveillance using high-definition coloscopes. However, this was a small case series (n = 24). The pooled estimated cancer prevalence rate from all these studies was 2.7% (95% CI: 0.2%-7.1%). The results are shown in a forest plot in Figure A5. Heterogeneity between studies was low (I2 calculated statistic = 19%; P = 0.29).

3.2.4 | Invisible LGD

Two cohort studies and one case series reported on prevalent cancer rates with a pre-operative diagnosis of invisible LGD. In two studies by Murphy et al (n = 3/141) and Kiran et al (n = 1/56), the prevalent cancer rate was 2%. The highest reported prevalent cancer rate was 18.2% in the smallest cohort reported by Ullman et al (n = 2/11). The pooled estimated cancer prevalence rate from all these studies was 2.4% (95% CI: 0.0%-8.5%). The results are shown in a forest plot in Figure A6. All of these studies included data mainly from an era when chromoendoscopy and high-definition imaging were not adopted into widespread practice. There was substantial between-study heterogeneity. Although the heterogeneity test did not reach statistical significance (P = 0.12), the I2 calculated statistic was still 53% and therefore suggestive of substantial between-study heterogeneity.

3.2.5 | Indefinite for dysplasia

Two cohort studies reported prevalent cancer rates, with a pre-operative diagnosis of indefinite for dysplasia, of 0.0% (n = 0/22) and 2.6% (n = 1/38). The latter study included a much higher proportion of patients with extensive colitis and primary sclerosing cholangitis. The pooled estimated cancer prevalence rate from these studies was 1.2% (95% CI: 0.0%-6.6%). The number of studies was too small to be able to assess heterogeneity for this patient group.

3.3 | Advanced neoplasia progression rate

Table 2 presents the summary of findings for the incidence rate of advanced neoplasia progression categorised by dysplasia grade, morphology and the lesions followed up after endoscopic resection (post-polypectomy).

3.3.1 | Visible HGD

There were 14 observational studies reporting on advanced neoplasia progression rates during surveillance follow-up after an initial diagnosis of visible HGD. The largest study was a Belgian retrospective multicentre cohort study of 27 IBD patients with visible HGD all within the extent of colitis, where 50% of the polyps were polyoid and 50% were nonpolyoid, and 85% of the polyps were endoscopically resected. Over the median follow-up time of 6.4 years (IQR 3.8-9.9), 14.8% (n = 4/27) of the patients developed a cancer. All other studies specifically reported on progression to advanced neoplasia after endoscopic resection of the visible HGD and are described in Section 3.3.2 and Table 3 (polypoid HGD followed up post-polypectomy) and Section 3.3.3 and Table 4 (nonpolyoid HGD followed up after polypectomy).

3.3.2 | Visible polyoid HGD—post-polypectomy

Seven studies (five cohort studies and two case series) reported on cancer progression rates after endoscopic resection of polyoid HGD (Table 3). All of the studies reported on very small numbers of polyoid HGD, and based completeness of resection on endoscopist judgement rather than histological assessment. This was due to difficulty in histological assessment of resection margins as a result of diathermy artefact or piecemeal resection. Resection methods included cold snare polypectomy,
and piecemeal or en bloc endoscopic mucosal resection. Most of the study cohorts included a mixture of HGD and LGD polyps where the proportion of HGD was in the minority, making pooled analysis inappropriate. Only one study included exclusively HGD polyps (n = 9), where two thirds were fully resected endoscopically and the rest surgically, and there was no progression to cancer over a mean follow-up period of 6 years. However, polyp recurrence was high at 62.5%. Kisel et al’s study using high-definition chromoendoscopy also showed no progression to cancer over an average follow-up of a median of 4.5 years. In two studies where chromoendoscopy was not used, there was progression to cancer at a rate of 25.0% (n = 3/12) over a median of 1.7 years and 40.0% (n = 2/5) over a median of 4 years. In the former study high-definition white light colonoscopy and polypectomy were performed by accredited endoscopists.

### 3.3.3 Visible nonpolypoid HGD—post-polypectomy

Six studies (all case series) reported on cancer progression rates after endoscopic resection of nonpolypoid dysplasia, which included a mixture of HGD and LGD polyps making pooled analysis inappropriate (Table 4). The endoscopic resection methods used piecemeal and en bloc endoscopic mucosal resection, endoscopic submucosal resection and hybrid techniques. Histological R0 resection (clear resection margins) varied from 67% to 100%. Patients in these studies were followed up intensively using chromoendoscopy and recurrent dysplasia was resected. Most of the studies had short median follow-up times of up to 2 years and did not show progression to advanced neoplasia over that follow-up. However, in a study with the longest follow-up time of 10.8 years after endoscopic submucosal dissection of high-risk...
HGD in which only 67% could be resected with histologically clear margins, half progressed to cancer.\textsuperscript{46}

### 3.3.4 | Invisible HGD

No studies reporting on cancer progression rates during surveillance follow-up of invisible HGD in the videoendoscopic era were found.

### 3.3.5 | Visible LGD

There were 21 observational studies reporting on advanced neoplasia progression rates during surveillance follow-up after an initial diagnosis of visible LGD.\textsuperscript{33-37,40-54} Due to the heterogeneity of the study populations involved, advanced neoplasia progression rate outcomes have been subanalysed and extracted according to the morphology of the LGD and whether it was endoscopically resected. These have been described in Section 3.3.6 and Table 3 (polypoid LGD followed up after polypectomy) and Section 3.3.7 and Table 4 (nonpolypoid LGD followed up after polypectomy). In the largest study of visible LGD progression (n = 155) by Choi et al.,\textsuperscript{13} polypoid morphology was significantly associated with a better prognosis than nonpolypoid LGD. The cumulative incidence of advanced neoplasia for polypoid LGD was 3.5% at 1 year and 6% at 5 years, and for nonpolypoid LGD it was significantly higher at 37% at 1 year and 62.5% at 5 years.\textsuperscript{13} However, this discrepancy is not only secondary to the morphology of the lesion. About 93% of the polypoid LGD in this patient cohort was successfully endoscopically resected, vs 39% of the nonpolypoid LGD. The nonpolypoid lesions were also likely to be multifocal compared with the polypoid lesions. Studies like this that have reported on advanced neoplasia progression rates for visible LGD, where not all of the lesions have been endoscopically resected or endoscopic resection has not been specified, are presented in Table A7.

#### 3.3.6 | Visible polypoid LGD—post-polypectomy

Nine studies (seven cohort studies and two case series) reported on advanced neoplasia progression rates while on surveillance follow-up after endoscopic resection of the index polypoid LGD (Table 3).\textsuperscript{23-37,40,48,52,53} The majority of these studies included a mixture of LGD and HGD polyps, again making pooled analysis inappropriate. Resection techniques included hot and cold biopsy, cold snare, piecemeal and en bloc endoscopic mucosal resection. Completeness of resection was based on endoscopist judgment rather than histological assessment. The average polyp diameters were 15 mm or less.

---

**TABLE 4** Advanced neoplasia progression rates during surveillance follow-up after endoscopic resection of NON-POLYPOID dysplasia

| Study             | Enrollment period | No. with non-polypoid dysplasia | % of polyps WITHIN coitiss extent | % full endoscopic resection | Median/mean polyp size (mm) | Dysplasia grading | Median/mean Follow-up (years) | No. progressed to AN | No. progressed to CRC | Reported AN progression (incidence) rate | Reported CRC progression (incidence) rate |
|-------------------|-------------------|---------------------------------|----------------------------------|-----------------------------|-----------------------------|---------------------|-----------------------------|-----------------------|----------------------|----------------------------------------|----------------------------------------|
| Iacopini et al. (2015)\textsuperscript{33} | 2009-2014         | 7                               | 100%                             | 100% in ESD (R0 in 71%)     | 15 (10-20)                  | 57% LGD; 43% HGD     | 1.75 (0.5-6)                | 0                     | 0                    | 0.0% over median 1.75 y                                      | 0.0% over median 1.75 y                                      |
| Kochhar (2017)\textsuperscript{37} | 2014-2017         | 6                               | NS                               | 100% in ESD (R0 in 85%)     | 40.7 (25-70)                | 50% LGD; 50% HGD     | 0.5                       | 0                     | 0                    | 0.0% over median 0.5 y                                      | 0.0% over median 0.5 y                                      |
| Suzuki (2017)\textsuperscript{40} | 2009-2016         | 26                              | 100%                             | 100% in ESD (R0 in 79%)     | 33 (12-73)                  | Approx. 60% LGD; 22% HGD | 2.75 (0.5-6.3)           | NS                    | 0                    | NS                                                | 0.0% over median 2.75 y                                      |
| Gulati (2018)\textsuperscript{42} | 2011-2016         | 9                               | 100%                             | 100% by EMR/ESD (R0 in 40%) | 48.3 (20-90)                | 100% LGD             | 2.3 (1-2.9)               | 2                     | 2                    | 22.2% over median 2.3 y                                      | 22.2% over median 2.3 y                                      |
| Kinoshita (2018)\textsuperscript{44} | 2011-2017         | 20                              | 100%                             | 100% in ESD (R0 in 76%)     | 34.9 ± 17.1                 | Approx. 50% LGD; 50% HGD | 1.75 (0.7-6.7)           | 1                     | 0                    | 5.0% over median 1.75 y                                      | 0.0% over median 1.75 y                                      |
| Yang (2019)\textsuperscript{45} | 2009-2017         | 11                              | 100%                             | 100% in ESD (R0 in 80%)     | 23 (12-48)                  | 73% LGD; 27% HGD     | 2.06 (0.4-5.4)           | 0                     | 0                    | 0.0% over median 2 y                                        | 0.0% over median 2 y                                        |
| Matsumoto (2019)\textsuperscript{46} | 1999-2015         | 7                               | 100%                             | 100% by ESD/hybrid ESD (R0 67%) | All were >10 mm            | 71% LGD; 29% HGD | LGD: 10.0 (7.1-12.3); HGD: 10.8 (10.5-11.1) | 3                    | 3                    | LGD: 40.0% over median 10 y; HGD: 50.0% over median 10.8 y | LGD: 40.0% over median 10 y; HGD: 50.0% over median 10.8 y |
| Yadav (2019)\textsuperscript{54} | 2012-2016         | 48 polyps (patient no. not extracted) | 100%                             | 100% by EMR/ESD/hybrid ESD (R0 status NS) | 1 (10-60)                  | Approx. 71.8% LGD | At most 4 y follow-up     | 0                     | 0                    | LGD: 0.0% over at most 4 y follow-up | LGD: 0.0% over at most 4 y follow-up |

Note: R0 indicates that resection margins were histologically cleared of dysplasia.

Abbreviations: AN, advanced neoplasia; CRC, colorectal cancer; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; HGD, high-grade dysplasia; LGD, low-grade dysplasia; NS, not specified.
Advanced neoplasia progression rates were reported to be 0.0%-5.0% at 1 year, and 0%-23.0% at 5 years. The highest 5-year advanced neoplasia rate of 23.0% was associated with a study which used high-definition white light imaging colonoscopy and not chromoendoscopy. Cancer progression rates ranged from 0.0% to 4.5% at 2 years and 0.0% to 13.6% at 4 years.

3.3.7 | Visible nonpolypoid LGD—post-polypectomy

Eight studies (one cohort study and seven case series) reported on advanced neoplasia progression rates while on surveillance follow-up after endoscopic resection of nonpolypoid LGD (Table 4). Again, the majority of the studies included a heterogeneous mixture of LGD and HGD polyps in small numbers, with short follow-up times, making pooled analysis inappropriate, but the majority showed no progression to HGD or cancer. R0 resection ranged from 40% to 100%. The only studies to demonstrate progression of nonpolypoid LGD to advanced neoplasia were case series of selected high-risk patients with large lesions which required resection with endoscopic submucosal dissection or hybrid techniques and R0 resections were the lowest. In Kinoshita et al’s Japanese case series, 20 dysplastic lesions, measuring on average 35 mm in diameter, were resected by endoscopic submucosal dissection and R0 resection was only achieved in 76%. During the post-resection follow-up, one case of metachronous HGD (5.0%) developed over a median of 1.75 years. In Gulati et al’s UK case series, nine LGD lesions with a mean diameter of 48 mm were resected using either endoscopic mucosal resection, endoscopic submucosal dissection or hybrid techniques. R0 resection was only achieved in 40%. Two patients (22.2%) developed cancer over the 2-year median follow-up time but these cancers arose in different colonic segments to the index dysplastic lesion suggesting that they did not occur due to incomplete resection. Matsumoto et al’s case series importantly described outcomes after the longest follow-up of median 10 years: 40.0% of the LGD progressed to cancer after endoscopic submucosal dissection or hybrid techniques. Again, these lesions were all high risk with size all greater than 10 mm, significant submucosal fibrosis and R0 resection only being achieved in 67%.

3.3.8 | Invisible LGD

Eight studies (seven cohort studies and one case series) reported on advanced neoplasia progression rates during surveillance follow-up after an initial diagnosis of invisible LGD (Table 5). All included small numbers with limited follow up, and/or heterogeneous cohorts with widely discrepant proportions of higher risk cases, for example concomitant primary sclerosing cholangitis and multifocal dysplasia. Thus, pooled analysis was deemed to be inappropriate. Advanced neoplasia progression rates were reported at 2.3%-13.0% at 1 year and 4.6%-44.0% at 2 years. Reported cancer progression rates ranged from 0.0% to 28.0% at median 2 years. In Ten Hove et al’s multicentre study, which used chromoendoscopy and/or high-definition endoscopes, the advanced neoplasia incidence rate was 2.29 cases per 100 patient-years and only 3.8% developed cancer over a median of 5 years follow-up. They also demonstrated that the incidence of invisible dysplasia has decreased in the most recent decade, with 88% of the invisible LGD lesions being detected before 2010 and 12% being detected after 2010.

3.3.9 | Indefinite for dysplasia

Six studies (five cohort studies and one case series) reported on advanced neoplasia progression rates while followed up after an initial diagnosis of indefinite for dysplasia (Table 6). Advanced neoplasia progression rates range from 2.4% to 14.6% at 2 years and 4.8% to 36.5% at 5 years. Cancer progression rates ranged from 0.0% to 1.2% at 2 years and 0.0% to 13.6% at 4 years. The study with the highest progression rates had a very small cohort of seven cases, all of which were invisible. The three largest cohort studies have found lower advanced neoplasia progression rates. Won-Tak Choi et al followed up 84 patients with a diagnosis of indefinite for dysplasia over a mean of 2.3 years. The advanced neoplasia progression rate was 2.4% and the cancer progression rate was 1.2%. Lai et al followed up a cohort of 59 patients over a longer mean follow-up of 6.8 years and found a 13.6% advanced neoplasia progression rate and a 5.1% cancer progression rate. The importance of histological re-review is substantiated in a pooled analysis of 26 patients with invisible indefinite for dysplasia, diagnosed across six Dutch academic centres. Van Schaik et al initially demonstrated a cumulative incidence of advanced neoplasia as 21% at 5 years, but after histological re-review by an expert gastrointestinal pathologist and reclassification of the indefinite for dysplasia, the cumulative incidence reduced substantially to 5% at 5 years.

4 | DISCUSSION

4.1 | Prevalent cancer rate

This meta-analysis calculated pooled estimates rates of prevalent cancer found at colectomy performed for a pre-operative diagnosis of visible HGD, invisible HGD, visible LGD, invisible LGD and indefinite for dysplasia to be 14%, 11%, 3%, 2% and 1% respectively. In contrast, studies in which the dysplasia has been diagnosed in the pre-videoeandoscopic era have shown much higher rates of prevalent cancer on colectomy. A 1994 systematic review of 10 small prospective surveillance studies by Bernstein et al demonstrated a prevalent cancer rate of 42% (n = 10/24) with endoscopically unresectable visible HGD. In 1994 Connell et al reported a prevalent cancer rate with invisible HGD as 44%, increasing to 67% (n = 8/12) after histological review and dysplasia reclassification in ulcerative colitis. Prevalent cancer rates with visible LGD in the same
pre-videoendoscopic era studies were reported at 19%-30%. \(^{60-62}\) A meta-analysis by Thomas et al., \(^{21}\) where most of the included studies were from the pre-videoendoscopic era, found a prevalent cancer rate with invisible LGD of 22% (n = 18/81). Fumery et al.'s meta-analysis \(^{20}\) has also suggested that rates of prevalent cancer have reduced over time. Studies published before 2000 were associated with a significantly higher prevalent cancer rate associated with pre-operative LGD (33%; 95% CI, 20-50) compared with studies published after 2000 (11%; 95% CI, 4-29).

It is suspected that standardisation of surveillance intervals, endoscopic technological advancements and routine use of second gastrointestinal histopathologist review have improved dysplasia diagnosis and resection. The consequence of this seems to be a reduction in missed dysplasia or cancers at colonoscopy, hence lower rates of incidental (prevalent) cancers found at colectomy. However, there are important limitations in the interpretation of the results of this meta-analysis: heterogeneity between studies could not be assessed for the outcomes for invisible HGD and indefinite for dysplasia, due to the limited number of studies (n = 2) included; there was substantial heterogeneity between studies reporting on visible HGD and invisible LGD prevalent cancer rates, part of which was due to the inclusion of small and heterogenous population cohorts; some studies may have included dysplasia located outside the extent of inflamed mucosa, \(^{28}\) whereas certain studies only included dysplasia cases located within the inflamed mucosa \(^{29,30}\) and thus displayed higher prevalent cancer rates. There is consensus that colonic dysplasia located outside the extent of colitis has a much better prognosis than true colitis-associated dysplasia, and is similar to that of a sporadic adenoma. \(^{9,15}\) The only category to show satisfactorily low between-study heterogeneity was visible LGD. The GRADE quality of evidence supporting the meta-analysis outcomes was determined to be low for visible LGD and very low for visible or invisible HGD, invisible LGD and indefinite for dysplasia due to the risk of bias in the study design, publication bias, indirectness and inconsistency in the results (Table 1).

### 4.2 Advanced neoplasia progression rate

In Fumery et al.'s \(^{20}\) meta-analysis of endoscopically visible LGD, the pooled incidence rate of advanced neoplasia was 1.0 per 100 patient-year follow-up (95% CI, 0-2.1), which did not take into

| Study          | Enrollment period | Extensive colitis (%) | Multifocal dysplasia (%) | PSC (%) | Second histopathologist review | No. with invisible LGD | Median/mean Follow-up (years) | No. progressed to AN | No. progressed to CRC | Reported AN progression (incidence) rate | Reported CRC progression (incidence) rate |
|----------------|-------------------|-----------------------|--------------------------|---------|-------------------------------|------------------------|-----------------------------|----------------------|----------------------|----------------------------------------|-----------------------------------------|
| Ullman (2002)  | 1990-1993         | 94%                   | NS                       | 28%     | Yes                           | 18                     | 2.6 (0.17-9.75)             | 4                    | 1                    | 13% at 1 y (95% CI = 0%-29%)          | 5.6% over median 2.7 y                  |
| Pekow (2010)   | 1994-2008         | NS                    | NS                       | 14%     | Yes                           | 13                     | 4.2 (SD 2.8)               | 1                    | 0                    | 7.7% over mean 4.2 y; 4.3 cases per 100 person-years | 0.0% over mean 4.2 y                   |
| Goldstone (2011)| 1994-2006         | 100%                  | 0%                       | 0%      | Yes                           | 32                     | 3.1 (IQR 1.1-6.0)          | 8                    | 3                    | 25.0% over median 3.1 y                | 9.3% over median 3.1 y                  |
| Van Schaik (2011)| 1990-2006         | 83%                   | 35%                      | 12%     | Yes                           | 25                     | 2.0 (0.2-8.5)              | 11                   | 7                    | 44.0% over median 2 y                  | 28.0% over median 2 y                  |
| Zisman (2012)  | 1987-2002         | 100%                  | 45%                      | 26%     | Yes                           | 19                     | 3.9 (1-13)                 | 4                    | NS                   | 21.1% over mean 3.9 y                  | NS                                     |
| Navaneethan (2013)| 1998-2011        | 100%                  | NS                       | 0%      | Yes                           | 37                     | 3.7 (IQR 2.3-6.2)          | 3                    | 1                    | 8.1% over median 3.7 y                 | 8.1% over median 3.7 y                  |
| Choi (2015)    | 1993-2012         | 100%                  | 21%                      | 6%      | Yes                           | 16                     | 4.0 (IQR 1.3-7.3)          | 6                    | 1                    | 6.7% at 1 y 21.9% at 5 y 56.7% at 10 y | 6.2% over median 4 y                   |
| Ten Houve (2017)| 2000-2014         | NS                    | NS                       | NS      | NS                            | 26                     | 4.7 (0.2-12.6)             | 3                    | 1                    | 11.5% over median 4.7 y; 2.29 cases per 100 person-years | 3.8% over median 4.7 y                  |

Abbreviations: AN, advanced neoplasia; CD, Crohn's disease colitis; CRC, colorectal cancer; IC, indeterminate colitis; IQR, interquartile range; NS, not specified; UC, ulcerative colitis.
consideration whether the lesion was endoscopically resected. The pooled advanced neoplasia incidence rate for invisible LGD was 6.1 per 100 patient-year follow-up (95% CI, 0.9-11.4) which was sixfold higher, but there was considerable between-study heterogeneity ($I^2 = 82\%$). Studies from the pre-videoendoscopic era and a study with exclusively primary sclerosing cholangitis patients were included in Fumery et al’s meta-analysis. In a meta-analysis of 20 mainly pre-videoendoscopic era studies by Thomas et al., invisible LGD was associated with a 14.6% ($n = 58/396$) progression rate to advanced neoplasia over a mean surveillance period of 12 years. A meta-analysis of 10 studies by Wanders et al., comprising 376 ulcerative colitis patients with polypoid dysplasia, demonstrated a pooled incidence of cancer after endoscopic resection of polypoid dysplasia of 0.5 cases per 100 patient-years of follow-up. However, studies where dysplastic lesions were found outside areas of colitis were also included in the meta-analysis, and a subgroup analysis by dysplasia severity was not performed.

The strength of this systematic review of videoendoscopic era studies is that it has attempted to clarify the risk of dysplasia progression to advanced neoplasia and specifically the risk of metachronous advanced neoplasia after endoscopic resection of colitis-associated dysplasia in the videoendoscopic era. In addition, this review has identified a further 20 studies not included in Fumery et al’s meta-analysis. The wide variation in outcomes demonstrated by our systematic review may be explained by a number of factors. Most of the current data on dysplasia progression risks are based on small retrospective cohort studies and case series with heterogenous endoscopic surveillance techniques and limited follow-up in some cases. All but one of the case series reporting on metachronous neoplasia after endoscopic resection of nonpolypoid dysplasia have median follow-up durations of 2 years or less. Image quality in the videoendoscopic era has also gradually improved over the last 30 years. In addition chromoendoscopy has been introduced into endoscopic surveillance practice from 2003 onwards and true high-definition imaging processors have been available from 2012 onwards. Most of the outcomes for invisible LGD in this systematic review were based on data from before the introduction of these endoscopic adjuncts. The most recent study where chromoendoscopy and high-definition imaging were part of routine surveillance practice demonstrated a lower incidence of invisible LGD as well as lower advanced neoplasia progression. Most of the follow-up studies of endoscopically resected dysplasia where these adjuncts were used with surveillance are associated with the lowest advanced neoplasia progression rates. The only studies to show significant advanced neoplasia progression despite use of these adjuncts were in one study where high-definition imaging but no chromoendoscopy surveillance was used after resection of LGD and HGD polyps and in two studies where high-definition chromoendoscopy surveillance was performed after resection of high-risk large nonpolypoid LGD lesions with significant submucosal fibrosis and where R0 resection rates were less than 70%.

Inconsistency in the outcomes also appears to be associated with variation in the completion of endoscopic resection of dysplasia achieved. Most of the studies reporting on polypoid dysplasia have defined resection completion based on endoscopist judgement rather than histological assessment. The use of diathermy during endoscopic mucosal resection and the potential need for piecemeal resection often makes histological assessment of resections difficult. Differing levels of skill and subjectivity in judging polypectomy completion between the endoscopists have not been accounted for in these studies. This and potential differences in the post-polypectomy surveillance intervals adhered to in independent centres may contribute to the variation in post-polypectomy metachronous advanced neoplasia seen.

### TABLE 6 Advanced neoplasia progression rates during surveillance follow-up after a diagnosis of indefinite for dysplasia

| Study          | Enrolment period | Extensive colitis (%) | PSC (%) | Second histopathologist confirmation of dysplasia | No. with indefinite for dysplasia | Median/mean Follow-up (years) | No. progressed to AN | No. progressed to CRC | Reported AN progression (incidence) rate | Reported CRC progression (incidence) rate |
|----------------|------------------|-----------------------|---------|-----------------------------------------------|---------------------------------|-------------------------------|----------------------|----------------------|----------------------------------------|----------------------------------------|
| Pekow (2010)   | 1994-2008        | NS                    | 14%     | Yes                                            | 7 (all invisible)               | 3.9 ± 3.2                     | 2                    | 1                    | 28.6% over mean 3.9 y; 7.3 cases per 100 person-years | 14.3% over mean 3.9 y                  |
| Van Schalk (2015) | 1990-2006       | 73%                   | 8%      | Yes                                            | 26                              | 4.5 (range 0.9-25)            | 5                    | 2                    | Before histological review: 21% (95% CI, 0.02%-0.4%) at 5 y After histological review: 5% (95% CI, 0.0%-0.2%) at 5 y; 2.4 cases per 100 person-years | 7.7% over median 4.5 y (before histological review) |
| Lai (2015)     | 1989-2004        | 49%                   | 14%     | 83% re-reviewed with no changes in classification | 59                              | 6.8 (3.1-9.7)                | 8                    | 3                    | 13.6% over median 6.8 y; 1.5 cases per 100 person-years | 5.1% over median 6.8 y                  |
| Won-Tok Choi (2015) | 2003-2013      | NS                    | 20%     | Yes                                            | 84                              | 2.3                          | 2                    | 1                    | 2.4% over mean 2.3 y                                  | 1.2% over mean 2.3 y                  |
| Murphy (2016)  | 1993-2012        | NS                    | 20%     | Yes                                            | 23                              | 1.5 (IQR 0.7-2.5)            | NS                   | 0                    | NS                                                   | 0.0% over median 1.5 y                  |
| Mahmoud (2019) | 2001-2017        | 74%                   | 32%     | Yes                                            | 53                              | 4.0 (IQR 3.0-4.8)            | 7                    | NS                   | 13.2% over median 4 y                                   | NS                                     |

**Abbreviations:** AN, advanced neoplasia; CD, Crohn’s disease colitis; CRC, colorectal cancer; IC, indeterminate colitis; IQR, interquartile range; NS, not specified; UC, ulcerative colitis.
The most recent studies in this review describe outcomes after the resection of nonpolypoid dysplasia using advanced techniques such as endoscopic submucosal dissection and hybrid techniques. These are technically difficult procedures performed by a small number of specialist endoscopists for high-risk lesions. Description of histological R0 resection success and intensive post-polypectomy surveillance intervals are strictly adhered to in these more recent studies, which have demonstrated that achieving R0 resection and adhering to close follow-up by expert endoscopists are associated with a lower risk of metachronous advanced neoplasia than previously thought. Therefore, although of low quality, the evidence supports the practice of continued close surveillance of patients following successful R0 resection of dysplastic lesions. It should be noted that very small numbers of HGD have been included in the post-polypectomy surveillance studies, making the evidence for choosing continued surveillance over colectomy after visible HGD resection of even lower quality than that for visible LGD. In addition, case series of large high-risk nonpolypoid dysplastic lesions where significant submucosal fibrosis resulted in low R0 resection rates and progression rates to cancer of 22%-40% with LGD, and 50% with HGD highlights the need for caution when deciding to delay a colectomy in these high-risk patients.

Analysis of the largest existing cohort study of LGD outcomes by Choi et al found that nonpolypoid shape (HR 16.5; 95% CI 6.8-39.8), lesion size greater than 10mm (HR 10.0; 95% CI 4.3-23.4), multifocality (HR 5.0; 95% CI 1.9-7.8), metachronous dysplasia (HR 3.5; 95% CI 1.6-7.5) and presence of a stricture (HR 7.4; 95% CI 2.5-22.1) were all significant risk factors for colorectal cancer development, and presence of two or more of these risk factors cumulatively increased the risk. Funemery et al’s meta-analysis of LGD outcomes found that concomitant primary sclerosing cholangitis (OR 3.4; 95% CI 1.5-7.8), invisibility (OR 1.87; 95% CI 1.04-3.36) and multifocality (OR 3.5; 95% CI 1.5-8.5) were significant risk factors for cancer development. Therefore, a patient with a combination of one or more of these risk factors should be surveilled more intensively by expert endoscopists. A lower threshold for elective colectomy should also be considered when deciding management with these higher risk patients.

No studies which reported on cancer progression rates after diagnosis of invisible HGD were identified. This is because most of these patients undergo colectomy rather than continue surveillance, based on the high incidences seen from pre-videoendoscopic era studies. Further data on outcomes of patients who have been followed up with surveillance for invisible HGD would need to be published before clinicians would consider recommending surveillance over colectomy. This review has shown that there remains considerable variation in the prognosis with invisible LGD; however, the rate of progression to cancer appears to have reduced in the most recent time period with routine use of high-definition imaging and/or chromoendoscopy. It is therefore not unreasonable for patients with unifocal invisible LGD to be closely monitored with surveillance rather than proceeding to a colectomy. However, the association of other high-risk factors, such as multifocality, concomitant primary sclerosing cholangitis and family history all need to be borne in mind when decision-making with these patients.

The largest cohorts of patients followed up after a diagnosis of indefinite for dysplasia showed lower rates of advanced neoplasia progression compared to invisible LGD. The best prognosis was achieved after confirmation of the diagnosis of indefinite for dysplasia by a second expert gastrointestinal histopathologist. Due to the interobserver incongruity in histological interpretation of indefinite for dysplasia, particularly on a background of inflammation, it seems entirely appropriate to repeat a surveillance colonoscopy after a period of therapy to reduce the background inflammation.

5 CONCLUSIONS

As endoscopic techniques in IBD surveillance, such as optical characterisation and resection of dysplasia, advance, clinicians have witnessed changes in the reported natural history of these lesions. Increasing expertise in dysplasia characterisation by histopathologists, as well as optimisation in medical therapy and standardisation of surveillance intervals are also likely to have produced better outcomes. The results of this meta-analysis suggest that dysplasia detected during surveillance in the videoendoscopic era are associated with lower rates of incidental cancers found at colectomy than previously thought. Dysplasia found within an inflamed colonic segment appears to be associated with higher prevalent cancer rates on colectomy than dysplasia detected proximal to the colitis extent. However, due to the very small numbers of heterogeneous studies involved, the quality of the evidence obtained from this meta-analysis remains low.

The findings from this systematic review suggest that the lowest rates of progression to advanced neoplasia, for dysplasia not managed with immediate colectomy but followed up with surveillance, tend to be where high-definition imaging and/or chromoendoscopy surveillance has been used and endoscopic resection of visible dysplasia has been histologically confirmed. When quoting individualised cancer risks to patients, clinicians need to be aware of the cumulative effects of various risk factors such as active inflammation, multifocality, previous history of dysplasia and the presence of primary sclerosing cholangitis. This review highlights the low quality of evidence on the prognosis of dysplasia in the videoendoscopic era. The lowest quality evidence is for nonpolypoid dysplasia that has been successfully resected. Current evidence is based mainly on retrospective cohort studies and case series with small, heterogeneous cohorts and short follow-up times. Interpretation of the data obtained from these studies is therefore limited. Larger, prospective studies are needed in order to make the evidence base used in shared decision-making more robust.

ACKNOWLEDGEMENTS

Jacqueline Kemp, Medical Librarian for Imperial College London, assisted in designing and conducting the full electronic literature search. All the authors approved the final version of the article.
Declaration personal interests: PJT has served as an advisory board member and speaker for Takeda. ALH has served as a consultant, advisory board member or speaker for AbbVie, Celltrion, Falk, Ferrigno, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Shire and Takeda.

Declaration of funding interests: This systematic review with meta-analysis was not funded by an external funding organisation or grant.

AUTHORSHIP

Guarantor of the article: Dr Misha Kabir.

Author contributions: All the authors contributed to the conception and design of the systematic review and meta-analysis, and critically revised the manuscript drafts until the final version was approved. MK performed the initial electronic literature search. MK and RF performed the study eligibility assessment, data extraction, analysis and interpretation. MK, RF and NA performed the methodological quality and risk of bias assessment of the data. PB is the statistician who performed the meta-analysis and produced the Forrest plots. MK was responsible for the drafting and revisions of the manuscript.

ORCID
Misha Kabir https://orcid.org/0000-0003-3991-1015
Rishi Fofaria https://orcid.org/0000-0002-1058-7584
Naila Arebi https://orcid.org/0000-0001-6976-1690
Phil J Tozer https://orcid.org/0000-0002-2532-7267
Ailsa L Hart https://orcid.org/0000-0002-7141-6076
Siwan Thomas-Gibson https://orcid.org/0000-0001-8922-6249
Adam Humphries https://orcid.org/0000-0001-5459-4551
Janindra Warusavitarne https://orcid.org/0000-0002-7950-2833
Omar Faiz https://orcid.org/0000-0001-6046-6281
Ana Wilson https://orcid.org/0000-0001-1117-1588

REFERENCES
1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
2. Caño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645-659.
3. Lutters MWMD, van Oljen MGH, van der Heijden GJMG, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789-799.
4. Jess T, Runge C, Biroulet LP. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-645.
5. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143:382-389.
6. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375-381.
7. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395:123-131.
8. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.
9. Magro F, Gionchetti P, Eliakim R, et al. European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649-670.
10. Bye WA, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2017;9:CD000279.
11. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968.
12. Kaltenbach T, Sandborn WJ. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. Gastrointest Endosc. 2017;86:962-971.
13. Choi C-H, Ignjatovic-Wilson A, Askari A, et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol. 2015;110:1461-1472.
14. Soetikno R, East J, Suzuki N, et al. Endoscopic submucosal dissection for nonpolypoid colorectal dysplasia in patients with inflammatory bowel disease: in medias res. Gastrointest Endosc. 2018;87:1085-1094.
15. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81:489-501.
16. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106.
17. Reyna VF, Nelson WL, Han PK, Pignone MP. Decision making and cancer. Am Psychol. 2015;70:105-118.
18. Han PKJ, Klein WMP, Lehman T, Killam B, Massett H, Freedman AN. Communication of uncertainty regarding individualized cancer risk estimates. Med Decis Making. 2011;31:354-366.
19. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334-339.
20. Fumery M, Dulai PS, Gupta S, et al. Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:665-674.e5.
21. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25:657-668.
22. Wanders L, Dekker E, Pullens B, Bassett P, Travis SPL, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:756-764.
23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
24. Munn Z, Moola S, Lisy K, Rittano D. Chapter 5: Systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z, eds. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017. p. 37. https://reviewersmanual.joannabriggs.org/. Accessed February 10, 2020.
25. Munn Z, Moola S, Rittano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Heal Policy Manag. 2014;3:123-128.
26. Schünemann H, Brozek J, Guyatt G, Oxman A, eds. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. The GRADE Working Group; 2013. https://guarantorhandbook.org/handbook. Accessed February 10, 2020.
27. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.
28. Murphy J, Kalkbrenner KA, Pemberton JH, et al. Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. Dis Colon Rectum. 2014;57:993-998.
29. Kiran RP, Ahmed Ali U, Nisar PJ, et al. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg. 2014;259:302-309.
30. Krugliak Cleveland N, Colman RJ, Rodriguez D, et al. Surveillance of IBD using high definition colonoscopes does not miss adenocarcinoma in patients with low-grade dysplasia. *Inflamm Bowel Dis*. 2016;22:631-637.

31. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. *Gastroenterology*. 2003;125:1311-1319.

32. Lai KK, Horvath B, Xie H, et al. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. *Inflamm Bowel Dis*. 2015;21:378-384.

33. Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. *Clin Gastroenterol Hepatol*. 2004;2:534-541.

34. Kisiel JB, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. *Inflamm Bowel Dis*. 2012;18:226-235.

35. Quinn AM, Farraye FA, Naini BV, et al. Polypectomy is adequate treatment for adenoma-like dysplastic lesions (DALMs) in Crohn's disease. *Inflamm Bowel Dis*. 2013;19:1186-1193.

36. Subramanian V, Chatu S, Echterdiek F, Banerjee A, Finlayson C, Pollok RCGG. Patients with endoscopically visible polyoid adenomatous lesions within the extent of ulcerative colitis have an increased risk of colorectal cancer despite endoscopic resection. *Dig Dis Sci*. 2016;61:3031-3036.

37. Krugliak Cleveland N, Huo D, Sadiq F, et al. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. *Gastroint Endosc*. 2018;87:1304-1309.

38. Cremer A, Demetter P, De Vos M, et al. Risk of development of more-advanced lesions in patients with inflammatory bowel diseases and dysplasia. *Clin Gastroenterol Hepatol*. 2019. [Epub ahead of print]. https://doi.org/10.1016/j.cgh.2019.05.062

39. Blonski W, Kundu R, Lewis J, Aberra F, Osterman M, Lichtenstein GR. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? *Scand J Gastroenterol*. 2008;43:698-703.

40. Patel N, Shah R, Jason H. Endoscopic surveillance patterns of polyoid dysplasia among patients with inflammatory bowel disease. *Am J Gastroenterol*. 2014;109:S512-S513.

41. Iacopini F, Saito Y, Yamada M, et al. Curative endoscopic submucosal dissection of large nonpolypoid superficial neoplasms in ulcerative colitis (with videos). *Gastroint Endosc*. 2015;82:734-738.

42. Kochhar G, Steele S, Sanaka M. Endoscopic submucosal dissection efficacy, safety and feasibility in patients with inflammatory bowel disease: a single center experience. *Am J Gastroenterol*. 2017;112:5450-5451.

43. Suzuki N, Toyonaga T, East JE. Endoscopic submucosal dissection of colitis-related dysplasia. *Endoscopy*. 2017;49:1237-1242.

44. Kinoshita S, Uraoka T, Nishizawa T, et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. *Gastroint Endosc*. 2018;87:1079-1084.

45. Yang D-H, Kim J, Song EM, et al. Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. *J Gastroenterol Hepatol*. 2019;9:1581-1589.

46. Matsumoto K, Oka S, Tanaka S, et al. Long-term outcomes after endoscopic submucosal dissection for ulcerative colitis-associated dysplasia. *Digestion*. 2019;1:11. [Epub ahead of print].

47. Zisman TL, Bronner MP, Rulyak S, et al. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. *Inflamm Bowel Dis*. 2012;18:2240-2246.

48. Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. *Inflamm Bowel Dis*. 2010;16:1352-1356.

49. Goldstone R, Itzkowitz S, Harpaz N, et al. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. *Gastroint Endosc*. 2011;74:1087-1093.

50. Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. *J Crohn's Colitis*. 2013;7:e684-e691.

51. ten Hove J, Mooiweer E, van der Meulen de Jong A, et al. Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: A retrospective study comparing chromendoscopy and white-light endoscopy. *Endoscopy*. 2017;49:161-168.

52. Yadav S, Lofthus EV, Harmsen WS, Wong Kee Song LM, Coelho-Prabhu N. Outcome of endoscopic resection of colonic polyps larger than 10 mm in patients with inflammatory bowel disease. *Endosc Int Open*. 2019;07:E994-E1001.

53. Branquinho D, Portela F, Freire P, Mendes S, Ferreira M. Dysplasia in inflammatory bowel disease: is endoscopic mucosal resection ready for primetime? *J Crohn's Colitis*. 2016;10:5390.

54. Gulati S, Emmanuel A, Burt M, Dubois P, Hayee B, Haji A. Outcomes of endoscopic resections of large laterally spreading colorectal lesions in inflammatory bowel disease: a single United Kingdom center experience. *Inflamm Bowel Dis*. 2018;24:1196-1203.

55. van Schaik FDM, ten Kate FJW, Offerhaus JGA, et al. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. *Inflamm Bowel Dis*. 2011;17:1108-1116.

56. Ullman T, Loftus EVJ, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. *Am J Gastroenterol*. 2002;97:922-927.

57. Murphy J, Kalkbrenner KA, Blas JV, et al. What is the likelihood of colorectal cancer when surgery for ulcerative-colitis-associated dysplasia is deferred? *Color Dis*. 2016;18:703-709.

58. Mahmoud R, Shah SC, Torres J, et al. Association between indefinite dysplasia and advanced neoplasia in patients with inflammatory bowel diseases undergoing surveillance. *Clin Gastroenterol Hepatol*. 2019. [Epub ahead of print]. https://doi.org/10.1016/j.cgh.2019.08.032

59. Choi W-T, Rabinovitch PS, Wang D, Westerhoff M. Outcome of “indefinite for dysplasia” in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer. *Hum Pathol*. 2015;46:939-947.

60. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? *Lancet*. 1994;343:71-74.

61. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for adenoma-like dysplastic lesions (DALMs) in Crohn's disease and dysplasia prognosis in the videoendoscopic era (1990 to present). *Aliment Pharmacol Ther*. 2020;52:5-19. https://doi.org/10.1111/apt.15778

SUPPORTING INFORMATION

Additional supporting information will be found online in the Supporting Information section.